Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.

ABSTRACT:

Background

Natalizumab treatment provides a model for non-inflammation-induced disease progression in multiple sclerosis (MS).

Objective

To study serum contactin-1 (sCNTN1) as a novel biomarker for disease progression in natalizumab-treated relapsing-remitting MS (RRMS) patients.

Methods

Eighty-nine natalizumab-treated RRMS patients with minimum follow-up of 3 years were included. sCNTN1 was analyzed at baseline (before natalizumab initiation), 3, 12, 24 months (M) and last follow-up (median 5.2 years) and compared to 222 healthy controls (HC) and 15 primary progressive MS patients (PPMS). Results were compared between patients with progressive, stable, or improved disability according to EDSS-plus criteria.

Results

Median sCNTN1 levels (ng/mL,) in RRMS (baseli

SUBMITTER: van Lierop ZY 

PROVIDER: S-EPMC8689420 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature